BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37993034)

  • 1. A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma.
    Lin H; Li G; Delamarre A; Ahn SH; Zhang X; Kim BK; Liang LY; Lee HW; Wong GL; Yuen PC; Chan HL; Chan SL; Wong VW; de Lédinghen V; Kim SU; Yip TC
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):602-610.e7. PubMed ID: 37993034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
    J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.
    Liang LY; Wong VW; Tse YK; Yip TC; Lui GC; Chan HL; Wong GL
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1509-1517. PubMed ID: 31025388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
    Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
    Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score.
    Shiha G; Soliman R; Mikhail N; Hassan A; Eslam M
    Liver Int; 2021 Nov; 41(11):2768-2776. PubMed ID: 34174150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    Kim HY; Lampertico P; Nam JY; Lee HC; Kim SU; Sinn DH; Seo YS; Lee HA; Park SY; Lim YS; Jang ES; Yoon EL; Kim HS; Kim SE; Ahn SB; Shim JJ; Jeong SW; Jung YJ; Sohn JH; Cho YK; Jun DW; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen HLA; Jang MJ; Lee YB; Kim YJ; Yoon JH; Papatheodoridis GV; Lee JH
    J Hepatol; 2022 Feb; 76(2):311-318. PubMed ID: 34606915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
    J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
    Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
    Qiu L; Xu S; Qiu Y; Liu Y; Zhang J
    J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
    Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
    Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Huang X; Wang H; Zhang W; Gu E
    Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.
    Singal AG; Mukherjee A; Elmunzer BJ; Higgins PD; Lok AS; Zhu J; Marrero JA; Waljee AK
    Am J Gastroenterol; 2013 Nov; 108(11):1723-30. PubMed ID: 24169273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.